homevideos Newshealthcare NewsCOVID vaccine: Novavax and J&J apply for emergency use approval in India
COVID vaccine: Novavax and J&J apply for emergency use approval in India
Novavax and Johnson & Johnson (J&J), both have applied for emergency use approval (EUA) for COVID vaccine in India. Novavax, with its Indian partner Serum Institute, has filed for approval in India, Indonesia and the Philippines for its recombinant nanoparticle COVID-19 vaccine Covovax.
Novavax and Johnson & Johnson (J&J), both have applied for emergency use approval (EUA) for COVID vaccine in India.
Novavax, with its Indian partner Serum Institute, has filed for approval in India, Indonesia and the Philippines for its recombinant nanoparticle COVID-19 vaccine Covovax.
Covovax has shown overall efficacy of 96.4 percent in phase 3 trials. However, more data is needed for efficacy against the more transmissible and prevalent delta strain. Serum has also done a bridge trial in India.
J&J's vaccine is a single dose vaccine and based on global trial data, it shows 85 percent efficacy in preventing severe COVID-19 disease, hospitalization and death, beginning 28 days after vaccination. A follow up study had also shown that the vaccine produced neutralising antibodies against the delta variant.
J&J has a supply collaboration with India's Biological-E for India and other countries through GAVI and the Covax facility.
Watch video for more.
(Edited by : Bivekananda Biswas)
First Published: Aug 6, 2021 6:03 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Delhi, Indore, Surat and Banswara — why these are the most challenging domains for Congress internally
May 4, 2024 1:53 PM
Congress nominee from Puri Lok Sabha seat withdraws, citing no funds from party
May 4, 2024 12:00 PM
Lok Sabha Polls '24 | Rahul Gandhi in Rae Bareli, why not Amethi
May 4, 2024 9:43 AM